pSivida eyes key market after wining Chinese patent:
This article was originally published in Clinica
Executive Summary
Australian firm pSivida has gained its first Chinese patent for its drug-delivery product, BrachySil, for primary liver cancer. The Perth-based firm says it is currently in discussions with commercialisation partners for BrachySil in China, which has the highest incidence of primary liver cancer in the world, with 345,800 cases in 2002. It expects to enter into a supply agreement with a local distributor responsible for obtaining regulatory approval, sales and marketing. The Chinese patent - No ZL 99807447.0 - provides protection for silicon implants comprising tissue compatible biodegradable silicon for drug delivery.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.